Company news
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) news
Jazz Pharmaceuticals Plc news releases on 6ix. Latest, Sep 15, 2026: Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
Press releases & updates
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
September 15, 2026
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
August 31, 2026
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
August 27, 2026
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
August 26, 2026
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
August 10, 2026
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
August 3, 2026
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
July 20, 2026
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
June 17, 2026
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
June 16, 2026
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
June 12, 2026
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
June 5, 2026
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
June 3, 2026
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
May 27, 2026
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
May 5, 2026
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
April 30, 2026
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
April 27, 2026
HealthCare Royalty Announces Royalty Monetization Agreement for Modeyso® Commercial Royalties
April 22, 2026
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
April 21, 2026
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
April 21, 2026
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting
April 9, 2026
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
April 1, 2026
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education
March 24, 2026
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
March 17, 2026
Rylaze (Jazz Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
March 13, 2026
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
February 24, 2026
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
February 17, 2026
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
February 10, 2026
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
January 12, 2026
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
January 7, 2026
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
January 5, 2026
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
December 16, 2025
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
December 4, 2025
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
December 1, 2025
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
November 17, 2025
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
November 17, 2025
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarc...
November 16, 2025
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
November 10, 2025
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance Its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies
November 10, 2025
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
November 4, 2025
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
October 27, 2025
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
October 21, 2025
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer
October 21, 2025
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
October 1, 2025
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
September 21, 2025
Design Therapeutics Appoints Justin Gover to Board of Directors
September 10, 2025
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
September 9, 2025
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
August 20, 2025
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
August 19, 2025
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
August 19, 2025
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
August 13, 2025